← Back to patent-cliff list
CAS 17106-13-7
2,4-dimethyl-1H-pyrrole-3-carboxylic acid
Codes: SUNT-017
Application context (from source-drug indications)
Pancreatic neuroendocrine tumourSunitinib MalateRenal cell carcinomaSunitinib MalateGastrointestinal stromal tumourSunitinib MalateOsteosarcomaSunitinib MalateSarcomaSunitinib MalateLymphomaSunitinib Malate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Sunitinib Malate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
N1,N1-diethylethane-1,2-diamine→N-(2-(diethylamino)ethyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide→ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate→2,4-dimethyl-1H-pyrrole-3-carboxylic acid→5-fluoro-2-oxoindoline-3-carbaldehyde
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 5-Fluoro-2-oxindole Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.